Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 1,738 trials

Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

Eosinophilic Gastritis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Achilles Tendinopathy: NGI226 Microparticles Study

We are investigating the safety and effects of NGI226 microparticles for patients with Achilles tendinopathy. This study aims to see if it helps restore tendon strength compared to a placebo.

Achilles Tendinopathy6-12 monthsEfficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Post-Traumatic Stress Disorder: Testing New Therapy

We are studying a new therapy called reconsolidation therapy for people with severe PTSD. This trial compares it to standard treatment and looks at whether adding propranolol can improve outcomes.

Post-Traumatic Stress Disorder≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Type 1 Diabetes: INVITED Trial on Flu Vaccine

We are studying whether influenza vaccination can help protect insulin-producing cells in individuals with early type 1 diabetes. This research aims to find new ways to support diabetes management.

Type 1 Diabetes>2 yearsEfficacy phase (II)Standard MedicinesEndocrinologyInfectious Diseases

Merkel Cell Carcinoma: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with advanced Merkel cell carcinoma. The goal is to see if this combination is effective and safe for those who haven't been treated before.

Merkel Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Acute Leukemia: 177Lu-PentixaTher Treatment

We are testing a new radioligand therapy for patients with relapsed or refractory CXCR4+ acute leukemia. The study aims to evaluate its effectiveness in treating this challenging condition.

Acute Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Semaglutide for Acute Ischemic Stroke

We are studying whether a new injection of semaglutide is safe and effective for non-diabetic patients right after an ischemic stroke. This trial aims to improve treatment options during this critical time.

Ischemic Stroke≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyNeurology

Fanconi Anemia: Long-Term Study of RP-L102 Infusion

We are evaluating the long-term safety and health effects of a gene therapy infusion for patients with Fanconi Anemia. This study looks at blood health and potential risks over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost Reimbursement

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Understanding Pain in Parkinson's Disease: PET Imaging Study

We are exploring how the serotonin system affects pain in people with Parkinson's disease. This study compares those with and without pain to learn more about their experiences and brain activity.

Parkinson's Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Arthritis from Cancer Immunotherapy: Tocilizumab Study

We are investigating whether adding tocilizumab to short-term glucocorticoids helps people with arthritis caused by cancer immunotherapy more than glucocorticoids alone. This study aims to improve arthritis control and patient outcomes.

Arthritis from Cancer TreatmentEfficacy phase (II)No PlaceboStandard MedicinesOncologyRheumatology

Migraine Relief: High-Flow Oxygen Therapy

We are studying whether high-flow oxygen therapy can help relieve migraine attacks in the emergency department. The trial also looks at its effects on related symptoms and overall patient experience.

Common Migraine1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurology

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

HER2-Positive Early Breast Cancer: Inavolisib Study

We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.

Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: mFOLFIRINOX with Radiation Therapy

We are studying whether adding high-dose radiation therapy to standard chemotherapy helps patients with borderline resectable pancreatic cancer have better surgical outcomes and survival rates.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology